| Ahmad Nawid Latifi, MD | |
|
1 Boston Medical Ctr Pl, Boston, MA 02118-2908 | |
| (313) 312-3006 | |
| Not Available |
| Full Name | Ahmad Nawid Latifi |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Cardiovascular Disease |
| Location | 1 Boston Medical Ctr Pl, Boston, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063933240 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 2836969 (Massachusetts) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ahmad Nawid Latifi, MD 1 Boston Medical Ctr Pl, Boston, MA 02118-2908 Ph: (617) 638-8000 | Ahmad Nawid Latifi, MD 1 Boston Medical Ctr Pl, Boston, MA 02118-2908 Ph: (313) 312-3006 |
News Archive
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preclinical data from AVEO's anti-RON antibody program which demonstrated the successful identification of antibodies with potent anti-tumor activity that demonstrated inhibition of the function of both wild type RON and the RONĪ160 variant, as well as a potential biomarker to identify tumors likely to respond to treatment with the anti-RON antibody.
Biologists have a new tool to track and videotape cells moving about inside living tissue.
As of Oct. 1, the health law's online marketplaces have been up and running for a year. News outlets offer status reports on what appears to have gone well, what problems remain as the second open enrollment period approaches and how these factors are playing politically.
Two patients with melanoma that had spread to the liver survived for at least 8.5 and 12 years after resection of the hepatic tumor and treatment with patient-specific immunotherapeutic vaccines.
FibroGen, Inc. (FibroGen) announced today the presentation of clinical data at the American Thoracic Society (ATS) International Conference supporting the safety and efficacy of FG-3019 in patients with idiopathic pulmonary fibrosis (IPF), a debilitating and life-threatening lung disease for which there is currently no approved therapy in the United States.
› Verified 6 days ago
Kaitlyn My-tu Lam, MBBS Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-724-7738 | |
Kui Toh Gerard Leong, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 55 Fruit Street, Massachusetts General Hospital, Boston, MA 02114 Phone: 617-726-8862 | |
Ruma Rajbhandari, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Boston, MA 02115 Phone: 617-525-6841 | |
Alaka Ray, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2066 | |
Meghan E Sise, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2862 | |
Aaron Dickstein, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 800 Washington St, Box 233, Boston, MA 02111 Phone: 617-636-5883 Fax: 617-636-9292 | |
Dr. Felicia Elizabeth Patch, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 801 Massachusetts Ave, Crosstown 2, Boston, MA 02118 Phone: 617-414-4376 Fax: 617-414-4676 |